Figure 1
From: Guizhi Fuling Wan as a Novel Agent for Intravesical Treatment for Bladder Cancer in a Mouse Model
Strategy used in intravesical treatment in a murine orthotopic bladder tumor model. Time schedules of treatment groups (A) and nontreatment control groups (B) are shown. Twenty-four hours after tumor implantation, animals in the treatment group underwent intravesical therapy with 100 µL GFW (180 mg/mL), 100 µL Mito-C (0.4 mg/mL) or PBS every other day (empty arrows pointing up), or 100 µL BCG (1 × 108 CFU/3 mL) therapy every week (empty arrows pointing down), while the control group received no treatment.